Amylin Analog

CagriSema (cagrilintide/semaglutide): pre-approval evidence, REDEFINE trial results, and what access teams should expect

Pipeline evidence review of Novo Nordisk's CagriSema, the first GLP-1/amylin combination for obesity. REDEFINE 1, 2, and 4 trial data,...